A photo of Christopher Dandoy.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Assistant Professor, UC Department of Pediatrics



Board Certified

About Me


I have always enjoyed caring for patients and their families, and I appreciate the unique bond that forms during treatment. But as a physician, I’ve experienced the devastating impact bloodstream infections can have on children. On more than one occasion, my team has successfully cured a child’s cancer using stem cell transplant, only to lose them later to a bloodstream infection.

As a result, my research focuses on identifying, testing and implementing clinical strategies to help improve outcomes after stem cell transplantation for malignancy. My clinical work compliments my research focus since I am the physician lead for the autologous stem cell transplant program, caring for many patients with leukemia. I prioritize patient safety, quality improvement, and the prevention of bloodstream infections and cardiopulmonary complications, such as pulmonary hypertension.

Cincinnati Magazine recognized me as a Top Doctor in 2019 and 2020. Also, our Cancer and Blood Diseases Institute Quality Improvement and Patient Safety team won the Ohio Patient Safety Institute’s Dr. Frank Dono Best Practice Award.

I am co-editor of the book Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation, published in 2017 by Springer. I’ve served in several local and national leadership roles, including the co-physician lead for the Solutions for Patient Safety (SPS) Pediatric Hematology-Oncology Central Line-Associated Bloodstream Infection (CLABSI) reduction collaboration.

I serve as the vice chair of the American Society of Transplant and Cellular Therapy (ASTCT) Committee on Quality Outcomes. I am co-chair of the Center for International Blood and Marrow Transplant Research (CIBMTR) Infection and Immune Reconstitution Working Committee.

Additional Languages

Portuguese, Spanish

Clinical Interests

Hematopoietic stem cell transplantation for children and young adults with malignancy or hemoglobinopathies

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Cardio-Oncology

My Locations

My Education

BS: Weber State University, Ogden, UT, 2003.

MD: University of Utah, Salt Lake City, UT, 2007.

MSc: University of Cincinnati, Cincinnati, OH, 2014.

Residency: Miami Children’s Hospital, Miami, FL, 2010.

Chief Residency: Miami Children’s Hospital, Miami, FL, 2011.

Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2014; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2014.

Certification: Pediatrics, 2010; Pediatric Hematology Oncology, 2015.

My Publications

Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Hsu, JW; Shaw, BE; Kim, S; Logan, BR; Sees, JA; Confer, DL; Pulsipher, MA; Shah, N; Switzer, GE; Abidi, MH; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1210-1217.

Analysis of chlorhexidine gluconate in skin using tape stripping and ultrahigh-performance liquid chromatography-tandem mass spectrometry. Zhao, X; Schaffzin, JK; Carson, J; Ankrum, A; Dobrzykowski, E; Haslam, DB; Dandoy, CE; Setchell, KD R. Journal of Pharmaceutical and Biomedical Analysis. 2020; 183:113111-113111.

Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al. Pediatric Transplantation. 2020; 24.

Complement blockade for TA-TMA: Lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, BL; Laskin, B; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, AS; Nelson, A; et al. Blood. 2020; 26:S138-S138.

Interferon-complement loop in transplant-associated thrombotic microangiopathy. Jodele, S; Medvedovic, M; Luebbering, N; Chen, J; Dandoy, CE; Laskin, BL; Davies, SM. Blood Advances. 2020; 4:1166-1177.

EASIX and mortality after allogeneic stem cell transplantation. Luft, T; Benner, A; Terzer, T; Jodele, S; Dandoy, CE; Storb, R; Kordelas, L; Beelen, D; Gooley, T; Sandmaier, BM; et al. Bone Marrow Transplantation. 2020; 55:553-561.

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Buchbinder, D; Brazauskas, R; Bo-Subait, K; Ballen, K; Parsons, S; Johns, T; Hahn, T; Sharma, A; Steinbergs, A; D'Souza, A; et al. Biology of Blood and Marrow Transplantation. 2020; 26:553-561.

Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. Dandoy, CE; Kim, S; Chen, M; Ahn, KW; Ardura, MI; Brown, V; Chhabra, S; Diaz, MA; Dvorak, C; Farhadfar, N; et al. JAMA Network Open. 2020; 3:e1918668-e1918668.

Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. Bhandari, R; Orgel, E; Rushing, T; Malicse, K; Evangelista, V; Jodele, S; Dandoy, CE. Biology of Blood and Marrow Transplantation. 2020; 26:150-156.

MBI-LCBI and CLABSI: more than scrubbing the line. Dandoy, CE; Alonso, PB. Bone Marrow Transplantation. 2019; 54:1932-1939.